We are live on ! Find out more
BTW

Boston Trust Walden Portfolio holdings

AUM $13.1B
1-Year Est. Return 24.63%
This Fund
S&P 500
This Quarter Est. Return
+17.89%
1 Year Est. Return
+24.63%
3 Year Est. Return
+61.41%
5 Year Est. Return
+82.17%
10 Year Est. Return
+348.28%
AUM
$7.41B
AUM Growth
+$1.13B
Cap. Flow
+$113M
Cap. Flow %
1.53%
Top 10 Hldgs %
20.78%
Holding
371
New
22
Increased
164
Reduced
130
Closed
11

Top Buys

Rank Stock Value
1
MEDP icon
Medpace
MEDP
+$33.5M
2
INTC icon
Intel
INTC
+$28.4M
3
HD icon
Home Depot
HD
+$24.6M
4
HMSY
HMS Holdings Corp.
HMSY
+$17.6M
5
ICUI icon
ICU Medical
ICUI
+$16.4M

Top Sells

Rank Stock Value
1
SYY icon
Sysco
SYY
+$25.4M
2
CLX icon
Clorox
CLX
+$19.6M
3
DHR icon
Danaher
DHR
+$18.4M
4
CBSH icon
Commerce Bancshares
CBSH
+$16M
5
BKNG icon
Booking.com
BKNG
+$15.1M

Sector Composition

Rank Sector Weight
1 Technology 19.79%
2 Healthcare 15.68%
3 Industrials 14.62%
4 Financials 13.46%
5 Consumer Discretionary 9.31%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
RY icon
251
Royal Bank of Canada
RY
$291B
$3.16M 0.04%
46,575
ADBE icon
252
Adobe
ADBE
$99.5B
$3.12M 0.04%
7,157
-425
-6% -$157K
SNN icon
253
Smith & Nephew
SNN
$13.3B
$3.09M 0.04%
81,080
+2,300
+3% +$91.1K
APH icon
254
Amphenol
APH
$198B
$3M 0.04%
125,476
-3,300
-3% -$73.7K
CNI icon
255
Canadian National Railway
CNI
$76.9B
$2.94M 0.04%
33,200
-2,000
-6% -$166K
PFE icon
256
Pfizer
PFE
$143B
$2.82M 0.04%
90,882
-343
-0.4% -$11.7K
LH icon
257
Labcorp
LH
$25.4B
$2.56M 0.03%
17,920
+990
+6% +$137K
ABBV icon
258
AbbVie
ABBV
$443B
$2.56M 0.03%
26,030
+276
+1% +$24.3K
EQNR icon
259
Equinor
EQNR
$97.7B
$2.45M 0.03%
169,105
-8,275
-5% -$116K
GIS icon
260
General Mills
GIS
$19.1B
$2.26M 0.03%
36,589
-700
-2% -$42.2K
DGX icon
261
Quest Diagnostics
DGX
$25.7B
$2.18M 0.03%
19,125
-200
-1% -$21.2K
KO icon
262
Coca-Cola
KO
$377B
$2.17M 0.03%
48,465
+1,738
+4% +$80.1K
NGG icon
263
National Grid
NGG
$80.4B
$2.13M 0.03%
39,577
AMCR icon
264
Amcor
AMCR
$20.8B
$1.95M 0.03%
38,194
-5,000
-12% -$233K
MA icon
265
Mastercard
MA
$506B
$1.88M 0.03%
6,343
-175
-3% -$49.3K
BF.A icon
266
Brown-Forman Class A
BF.A
$13.4B
$1.86M 0.03%
32,400
VMBS icon
267
Vanguard Mortgage-Backed Securities ETF
VMBS
$15.4B
$1.83M 0.02%
33,737
+6,275
+23% +$342K
SPGI icon
268
S&P Global
SPGI
$121B
$1.74M 0.02%
5,290
+470
+10% +$141K
SPY icon
269
State Street SPDR S&P 500 ETF Trust
SPY
$790B
$1.73M 0.02%
5,624
-139
-2% -$40.7K
CMA
270
DELISTED
Comerica
CMA
$1.64M 0.02%
43,045
-312,350
-88% -$10.9M
PSX icon
271
Phillips 66
PSX
$84.9B
$1.56M 0.02%
21,766
-850
-4% -$60.2K
T icon
272
AT&T
T
$159B
$1.52M 0.02%
66,700
-7,823
-10% -$178K
QCOM icon
273
Qualcomm
QCOM
$155B
$1.39M 0.02%
15,223
-900
-6% -$72.2K
NEE icon
274
NextEra Energy
NEE
$181B
$1.17M 0.02%
19,468
-1,192
-6% -$71.3K
VEU icon
275
Vanguard FTSE All-World ex-US ETF
VEU
$66.6B
$1.16M 0.02%
24,250
-3,742
-13% -$168K

Similar funds

Boston Trust Walden's Q2 2020 Portfolio in Review

As of Q2 2020, Boston Trust Walden held 371 positions worth $7.41B, up 18% from $6.27B the previous quarter. Its ten largest holdings account for 21% of the portfolio.

Boston Trust Walden's Q2 2020 filing shows 22 new, 164 increased, 130 reduced and 11 closed positions. Its largest new stake was Medpace: 393,535 shares worth $36.6M. The largest sale was Sysco, an estimated $25.4M.

By sector, the portfolio is most concentrated in Technology at 20% of assets, up from 18% a quarter earlier, followed by Healthcare and Industrials.

  • Boston Trust Walden's largest Q2 2020 buy was Medpace: 393,535 shares worth $36.6M.
  • Boston Trust Walden added most to Intel in Q2 2020, an estimated $28.4M increase.
  • Boston Trust Walden's biggest Q2 2020 reduction was Sysco, cutting an estimated $25.4M.
  • Boston Trust Walden fully exited Booking.com in Q2 2020, selling an estimated $15.1M.
  • Boston Trust Walden's ten largest holdings make up 21% of its $7.41B portfolio in Q2 2020.
  • Boston Trust Walden opened 22 new positions and closed 11 in Q2 2020.
  • Boston Trust Walden's portfolio value rose 18% quarter-over-quarter to $7.41B.

Based on Boston Trust Walden's 13F filing for Q2 2020, filed 23 Jul 2020.